Compare iShares Core MSCI EAFE ETF (IEFA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs TransMedics Group Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 69× TransMedics Group Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and TransMedics Group Inc for 24 Days on average.
| IEFA | TMDX | |
|---|---|---|
Market Cap | $189.19B | $2.74B |
Volume | 8,441,787 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $150.42 |
52-Week Low | $85.06 | $61.99 |
Typical Hold Time | 40 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $95.87, down 0.34% with bearish technical signals dominating. The ETF manages $196 billion in assets and focuses on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors like Schwab's SCHF and State Street's SPDW, though some alternatives have shown stronger recent performance.
The outlook remains cautious given bearish technical indicators and competitive pressure from lower-cost alternatives. Key risks include international market volatility and currency fluctuations, while the fund's scale and diversification provide stability for long-term international exposure seekers.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
